MoonLake Immunotherapeutics Overview
Valuation check: MLTX's P/E ratio is -4.09, below the sector sector average of 34.56.
Get informed when a big investor buys or sells
+ Follow-4.09
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, MLTX shows a P/E ratio of -4.09. That is below the sector sector average of 34.56. Scroll down for historical charts and peer comparison views.
The its sector sector average P/E ratio is about 34.56. MoonLake Immunotherapeutics is at -4.09, which is lower that average. That is roughly 111.8% below the sector mean. Use the comparison chart on this page to see how MLTX stacks up against individual peers as well.
Investors watch MLTX's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. MoonLake Immunotherapeutics's latest reading is -4.09. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has MoonLake Immunotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -4.09) with ownership activity and broader fundamentals.
